A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection

Clicks: 479
ID: 113374
1996
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #6 of 44 articles by views in archives of internal medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A monthly application of mupirocin ointment in staphylococcal carriers reduces the incidence of nasal colonization, which in turn lowers the risk of skin infection.
Reference Key
r1996archivesa Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Raz R;Miron D;Colodner R;Staler Z;Samara Z;Keness Y;;
Journal archives of internal medicine
Year 1996
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8638999
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent middle aged Child Recurrence Clinical Trial Randomized Controlled Trial Double-Blind Method mupirocin / administration & dosage mupirocin / therapeutic use* pmid:8638999 r raz d miron y keness topical carrier state* nose / microbiology* staphylococcal skin infections / prevention & control* staphylococcus aureus / isolation & purification*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.